AMAG Pharma (AMAG) Posts Q4 EPS of $0.10 on Tax Reform Gain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Pharmaceuticals (AMAG) PT Raised to $25 at Cowen as Execution Improves
February 27, 2018 11:59 AM ESTCowen raised its price target on AMAG Pharmaceuticals (NASDAQ: AMAG) to $25.00 (from $20.00) while maintaining a Market Perform rating.
Analyst Ken Cacciatore commented, "AMAG has had a very nice start to '18, with the Makena autoinjector approval a solid step in the recovery. While... More
